MediGene AG · LS:A40ESG

MediGene — Q1 2011 Earnings Presentation

17 slides from MediGene's earnings presentation, May 13, 2011

  1. Slide 1: Analyst Conference Call Financial Result 3-Months 2011

    Analyst Conference Call Financial Result 3-Months 2011 May 13, 2011 Dr. Frank Mathias, Chief Executive Officer Arnd Christ, Chief Financial Officer

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila

  3. Slide 3: Recent achievements

    Recent achievements

  4. Slide 4: Successful start in 2011

    Successful start in 2011  Positive net result in Q1 2011  Eligard ® rights transferred to Astellas Pharma for EU countries; milestone payment of € 15 million received  Veregen® approved in Spain  Conclusion of several Veregen® partnership agreements  Preclinical trials with RhuDex® conducted su

  5. Slide 5: Financial results

    Financial results

  6. Slide 6: Positive result forms basis for future growth

    Positive result forms basis for future growth  Increased revenue from continued and discontinued operations of € 27.9 million, including milestone payments of € 20 million from Astellas  Positive EBITDA of € 19.2 million  Positive net result of € 17.0 million  Cash and cash equivalents as at Mar

  7. Slide 7: Revenue increase driven by Eligard Milestones

    Revenue increase driven by Eligard® milestones In € million  Eligard®: Revenue from continued and discontinued operations • Milestones of € 20 million from Astellas included in revenue from discontinued operations 132% 27.9 • Since March 2011 royalty stream of 2% 12.0 accounted for as other income

  8. Slide 8: In market sales of Eligard and Veregen show continuing growth

    In market sales of Eligard® and Veregen® show continuing growth Eligard In Market Sales Veregen In Market Sales in € million in € thousand Jan Feb Mar Jan Feb Mar 2010 2011 2010 2011 8

  9. Slide 9: Veregen: New partnership agreements closed in 2011 worldwide

    Veregen®: New partnership agreements closed in 2011 worldwide Triton Pharma (Canada) Will-Pharma (Benelux) Meditrina (Romania, Bulgaria) Laboratoires Expanscience (France) Pierre Fabre (Mexico, Central America, Vene- zuela, Colombia) Partnered Partnered in 2011 Status: May 13, 2011 9

  10. Slide 10: Development of R&D and SG&A expenses

    Development of R&D and SG&A expenses In € million R&D  Strict reduction of expenses particularly in the fields of • Personnel : -34% 4.1 2.0 • Third-party expenses: -80% -50% Q1 2010 Q1 2011 SG&A  Savings in the fields of • Personnel: -14% • Third-party expenses: -56% 2.0 -16% 1.6 Q1 2010 Q1 2011

  11. Slide 11: High revenues lead to positive result

    High revenues lead to positive result In € million EBITDA  Positive EBITDA and net result Q1 2010 Q1 2011  Strategic steps taken in 2010 begin to bear fruit 19.2 • One-time milestone payments -2.4 from transfer of Eligard-rights lead to high revenues Net result for the period Q1 2010 Q1 2011 • Co

  12. Slide 12: Milestone payment for transfer of Eligard rights increased cash balance

    Milestone payment for transfer of Eligard rights increased cash balance In € million 0.1 0 -0.4 14.5 18.8 4.8 Cash balance Net cash used Net cash used Net cash Foreign Cash balance Jan. 1, 2011 by operating by investing from financing exchange Mar. 31, 2011 activities activities activities differen

  13. Slide 13: Outlook

    Outlook

  14. Slide 14: Financial outlook 2011

    Financial outlook 2011  Revenues* • From continued and discontinued operations: € 32-38 million • Thereof one-time milestone payments for Eligard® totaling € 20-25 million  EBITDA* • € 10-16 million *Outlook based on current product portfolio  14

  15. Slide 15: Project objectives

    Project objectives  Eligard ® • Transfer of EU rights to Astellas  • Transfer of rights for non-EU countries to Astellas  Veregen® • Submission of additional market approval applications in Europe • Conclusion of further marketing partnership agreements  EndoTAG®-1 • Achieve global or regional l

  16. Slide 16: Q&A

    Q&A Frank Mathias, CEO & Arnd Christ, CFO

  17. Slide 17: MediGene AG contact details

    MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com

MediGene — Q1 2011 Earnings Presentation on 6ix